Mineralys Therapeutics presents new leptin analysis from Target-HTN trial of lorundrostat

Mineralys Therapeutics, Inc.

Elevated BMI (>30 kg/m²) predicted enhanced systolic BP reduction: placebo-adjusted drops of 16.7 mmHg (50 mg) and 12.3 mmHg (100 mg).
New analysis shows increased serum leptin correlates with higher BMI, suggesting leptin as a biomarker for responsive patients.
Target-HTN results support transition to late-stage development; Advance-HTN pivotal trial enrolling, Launch-HTN expected H2 2023.
Data presented at AHA Scientific Sessions 2023 in Philadelphia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.